CROI 2024 Program Guide

General Information

ABIM MOC Points Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit Claiming CME Credits, ABIM MOC Points, or a Certificate of Participation During the conference, links to the daily evaluations will be available on the CROI website The overall evaluation with detailed instructions on how to claim credits will be provided after the conference You will need the email address used to register for this conference and your confirmation number (on your badge) to access this page To obtain CME credits, ABIM MOC points, or a Certificate of Participation for CROI, overall evaluation, posttest assessment, and claim forms must be submitted by April 8, 2024 Once the final evaluation and posttest are submitted, your certificate will be available on your IAS–USA profile on the IAS–USA website To determine the number of CME credits, ABIM MOC points, or hours of participation that can be claimed, calculate the time spent attending conference activities, including premeeting workshops, opening session lectures, plenary lectures, concurrent interactive sessions and symposia, and selected special sessions For example, if you attended 2 plenary talks (8:30 to 9:30 AM) and a symposium (4:00 to 5:30 PM), you would have 2 5 hours to apply toward CME credits or ABIM MOC points (if applicable) for that day At the end of CROI, please add the total hours you attended A CME/ABIM MOC hour worksheet can be found on the CROI website Disclosure of Financial Relationships In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, the Scientific Leadership Board, Governance Board, and program planners) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the delivery of the CME activity Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients” IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the slides prior to the presentation of educational content Drug and Product Disclaimer This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration Please consult full prescribing information before using any medication or product mentioned in this activity

General Information

CROI 2024 12